Health Care

Cardinal Health’s strategic blend of tech‑driven logistics, value‑based reimbursement alignment, and cost‑efficient operations fuels 15% CAGR growth and high margins in the US healthcare supply chain.

Galderma’s April 27 share rise signals investor trust as it pivots from injectables to energy‑based aesthetic treatments, tackling patent cliffs, pricing resilience, and M&A to secure future growth in Switzerland’s competitive pharma market.

Explore how Haleon’s share buybacks and bone‑health supplements impact investors and patients alike, with key market insights and safety data.

AbbVie’s FDA filing for subcutaneous SKYRIZI® could slash induction costs by 50 %, boost patient adherence, and expand IBD market reach.

German markets see modest gains as Sartorius AG’s analyst upgrade fuels a strong rally, highlighting how positive research sentiment can boost the TecDAX and MDAX indices.

How the Supreme Court’s Roundup ruling could cost Bayer AG $3‑$5 bn, shift agro‑chemical regulation and raise healthcare supply‑chain costs.

Merck KGaA’s modest share drop on 27 Apr 2026 stems mainly from ex‑dividend mechanics, not fundamentals. Despite a €2.20 payout, the company’s solid market cap, regulatory resilience, and growth prospects in digital health and sustainable chemistry …

UnitedHealth Group’s insider move, earnings beat, and tightening Medicare regulation: a nuanced look at how Optum’s cost‑control and digital push drive value, while new audit pressures test future growth.

Pfizer’s latest Form 4 filings reveal phantom‑stock grants to non‑employee directors, boosting incentive alignment without diluting shares or affecting capital structure.

Explore how Novo Nordisk’s AI partnership, coramitug breakthrough, and buy‑back plan could reshape its growth, diversify its pipeline, and impact investors.